Novo Nordisk Reports Strong Phase 3 Results for Denecimig in Hemophilia A
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
Novo Nordisk
Advertisement
Novo Nordisk Oral Semaglutide Shows Pediatric Breakthrough
Bagsværd, Denmark – April 23, 2026 In a major advancement for pediatric diabetes care, Novo Nordisk announced positive Phase...
Novo Nordisk Reports Etavopivat Phase 3 Breakthrough
Bagsværd, Denmark, April 20, 2026 Novo Nordisk has announced breakthrough Phase 3 clinical trial results for etavopivat, a first-in-class...
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Novo Nordisk Awiqli FDA Approval Weekly Insulin
Bagsværd, Denmark – March 27, 2026 Novo Nordisk announced that the U.S. FDA has approved Awiqli® (insulin icodec-abae), the...
Advertisements
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Novo Nordisk, Vivtex Partner on Oral Obesity Drugs
February 25, 2026 – Bagsværd, Denmark & Boston, Massachusetts, USA Novo Nordisk and Vivtex Corporation have announced a strategic...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent
BAGSVAERD, DENMARK | December 31, 2025 — Novo Nordisk announced that China’s Supreme People’s Court has upheld the validity...
Novo Nordisk’s Amycretin Shows Strong Phase 2 Diabetes Results
Bagsværd, Denmark, Nov. 25, 2025 — Novo Nordisk has announced positive Phase 2 clinical trial results for amycretin, a...
Novo Nordisk Reshapes Leadership Structure Following EGM Vote
Dateline: November 14, 2025 — Bagsværd, DenmarkNovo Nordisk A/S announced a series of major Board of Directors changes following...
Advertisement
